Search

Your search keyword '"Mohamed Shehab"' showing total 6 results
Start Over Author "Mohamed Shehab" Journal cancers
6 results on '"Mohamed Shehab"'

3. Intraoperative Extra Corporeal Membrane Oxygenator for Lung Cancer Resections Does Not Impact Circulating Tumor Cells

Author

Petrella, Francesco, primary, Zorzino, Laura, additional, Frassoni, Samuele, additional, Bagnardi, Vincenzo, additional, Casiraghi, Monica, additional, Bardoni, Claudia, additional, Mohamed, Shehab, additional, Musso, Valeria, additional, Simonini, Emanuele, additional, Rossi, Fabiana, additional, Alamanni, Francesco, additional, Venturino, Marco, additional, and Spaggiari, Lorenzo, additional

Published
2022
Full Text
View/download PDF

5. Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review

Author

Gallina, Filippo Tommaso, primary, Bertolaccini, Luca, additional, Forcella, Daniele, additional, Mohamed, Shehab, additional, Ceddia, Serena, additional, Melis, Enrico, additional, Fusco, Francesca, additional, Bardoni, Claudia, additional, Marinelli, Daniele, additional, Buglioni, Simonetta, additional, Visca, Paolo, additional, Cappuzzo, Federico, additional, Spaggiari, Lorenzo, additional, and Facciolo, Francesco, additional

Published
2022
Full Text
View/download PDF

6. The Role of Immunotherapy or Immuno-Chemotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review.

Author

Mohamed, Shehab, Bertolaccini, Luca, Galetta, Domenico, Petrella, Francesco, Casiraghi, Monica, de Marinis, Filippo, and Spaggiari, Lorenzo

Subjects
*LUNG cancer, *THORACIC surgery, *LUNG tumors, *EARLY detection of cancer, *TREATMENT effectiveness, *TUMOR classification, *CANCER patients, *QUALITY of life, *IMMUNOTHERAPY, *PATIENT safety, *OVERALL survival
Abstract

Simple Summary: Surgical resections remain the gold standard for early stages non-small-cell carcinoma (NSCLC) and may be considered for locally advanced tumors. Medical treatment has changed drastically in recent years, especially for advanced stages, for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. The addition of radical surgical resection following immunotherapy or immuno-chemotherapy is feasible and safe with low surgical-related mortality and morbidity in selected patients with initially unresectable NSCLC. Many new treatment modalities for non-small-cell carcinoma (NSCLC) have been described in the last two decades. Surgical resections remain the gold standard for early stages and may be considered for locally advanced tumors. Medical treatment has changed drastically in recent years, especially for advanced stages, for which the development of immunotherapy and molecular targeted therapy significantly increased survival and quality of life. The addition of radical surgical resection following immunotherapy or immuno-chemotherapy is feasible and safe with low surgical-related mortality and morbidity in selected patients with initially unresectable NSCLC. However, data from multiple ongoing trials with overall survival as the primary endpoint should be awaited before this strategy is introduced into the standard of care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results